Recovery Initiation and Management After Overdose (RIMO) Experiment
Completed · Not applicable
Conditions studied: Opioid-use Disorder
In brief
This study targets individuals in Chicago who have received naloxone administered by first responders within the past week to reverse an overdose, but who have not entered into MAT. Study participants will be recruited through partnerships with the Chicago Fire Department (CFD) and/or Police Department (CPD); first responders will be trained to seek consent from individuals who are alert and oriented after receiving naloxone for future contacts by research staff as part of the naloxone standard protocol. Those who consent will be contacted and screened for study eligibility ideally within one week of naloxone administration; eligible participants will be randomly assigned either to the control group, i.e., referral to MAT as usual, or to Recovery Initiation and Management after Overdose (RIMO), an assertive linkage and recovery support intervention. This intervention builds on an evidence-based intervention for treatment linkage, monitoring, and recovery support evaluated in 3 prior clinical trials by the study team.
Key facts
- Study ID
- NCT03895827
- Run by
- Chestnut Health Systems
- People needed
- 251
- Starts
- 2022-04-01
- Expected to finish
- 2025-06-26
- Last updated by the study team
- 2026-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- experienced an opioid overdose reversed with naloxone administered by first responders on a participating team within the past week
- not in treatment during the past 30 days
- screen positive for an OUD
You may not qualify if…
- under age 18
- unable to speak and understand English
- not residing in Chicago
- cognitively unable to provide informed consent
Where it is running
- Chestnut Health Systems — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.